scholarly journals PD-L1 Expression in Muscle Invasive Urothelial Carcinomas as Assessed via Immunohistochemistry: Correlations with Specific Clinical and Pathological Features, with Emphasis on Prognosis after Radical Cystectomy

Life ◽  
2021 ◽  
Vol 11 (5) ◽  
pp. 404
Author(s):  
Ioan Alin Nechifor-Boilă ◽  
Andrada Loghin ◽  
Adela Nechifor-Boilă ◽  
Myriam Decaussin-Petrucci ◽  
Septimiu Voidăzan ◽  
...  
Keyword(s):  
Radical Cystectomy ◽  
Distant Metastases ◽  
Lymph Node Involvement ◽  
Histological Variant ◽  
Node Involvement ◽  
Positive Score ◽  
Checkpoint Inhibitor Therapy ◽  
N Stage ◽  
Combined Positive Score ◽  
Muscle Invasive

In the present study, we analyzed Programmed Death Ligand-1 (PD-L1) expression in radical cystectomy (RC) specimens from patients with muscle-invasive urothelial carcinoma (UC), in order to assess any correlations with specific clinicopathological features and its potential prognostic value. A multi-institutional study was performed within the departments of urology and pathology at the Mureș County Hospital, Romania, and Centre Hospitalier Lyon Sud, France. Sixty-nine patients with MIBC were included, for whom tumor histology (conventional versus histological variant/differentiation), tumor extension (T), lymph node involvement (N), and distant metastases (M) were recorded. PD-L1 immunostaining was performed using the 22C3 clone and was interpreted using the combined positive score (CPS) as recommended (Dako Agilent, Santa Clara, CA, USA). Positive PD-L1 immunostaining was more prevalent among UCs with squamous differentiation compared to conventional UCs and trended towards an improved OS (p = 0.366). We found the T stage to be a risk factor for poor survival in PD-L1-positive patients (HR 2.9, p = 0.021), along with the N stage in PD-L1-negative patients (HR 1.98, p = 0.007). No other clinicopathological factor was found to be significantly associated with PD-L1 positivity. Thus, we confirm the need for PD-L1 immunostaining prior to initiating immune checkpoint inhibitor therapy for a more accurate assessment of the patients’ chances of responding to treatment.

Small Intestine: Adenocarcinoma

2017 ◽  
Author(s):  
Joel M Baumgartner ◽  
Sudeep Banerjee ◽  
Jason K Sicklick
Keyword(s):  
Lymph Node ◽  
Small Bowel ◽  
Systemic Chemotherapy ◽  
Imaging Techniques ◽  
Distant Metastases ◽  
Lymph Node Involvement ◽  
Small Bowel Adenocarcinoma ◽  
Stage Disease ◽  
Node Involvement ◽  
Inflammatory Bowel

Adenocarcinoma is the second most common nonduodenal small bowel tumor. Small bowel adenocarcinoma has risk factors similar to those of colorectal adenocarcinoma but is rarer and less well understood. Diagnosis relies on advanced imaging techniques as well as endoscopy or enteroscopy for tissue diagnosis. Aggressive biology and vague symptoms in early disease cause a majority of patients to present with late-stage disease. Adenocarcinomas with lymph node involvement should be treated with resection and systemic chemotherapy. In contrast, systemic chemotherapy alone should be employed in cases with distant metastases unless the primary tumor is bleeding, perforated, or causing a bowel obstruction.   This review contains 4 figures, 5 tables and 17 references Key words: adenocarcinoma, chemotherapy, enteroscopy, hereditary syndrome, inflammatory bowel disease, lymph node, mesentery, small bowel  

Small Intestine: Adenocarcinoma

2017 ◽  
Author(s):  
Joel M Baumgartner ◽  
Sudeep Banerjee ◽  
Jason K Sicklick
Keyword(s):  
Lymph Node ◽  
Small Bowel ◽  
Systemic Chemotherapy ◽  
Imaging Techniques ◽  
Distant Metastases ◽  
Lymph Node Involvement ◽  
Small Bowel Adenocarcinoma ◽  
Stage Disease ◽  
Node Involvement ◽  
Inflammatory Bowel

Adenocarcinoma is the second most common nonduodenal small bowel tumor. Small bowel adenocarcinoma has risk factors similar to those of colorectal adenocarcinoma but is rarer and less well understood. Diagnosis relies on advanced imaging techniques as well as endoscopy or enteroscopy for tissue diagnosis. Aggressive biology and vague symptoms in early disease cause a majority of patients to present with late-stage disease. Adenocarcinomas with lymph node involvement should be treated with resection and systemic chemotherapy. In contrast, systemic chemotherapy alone should be employed in cases with distant metastases unless the primary tumor is bleeding, perforated, or causing a bowel obstruction.   This review contains 4 figures, 5 tables and 17 references Key words: adenocarcinoma, chemotherapy, enteroscopy, hereditary syndrome, inflammatory bowel disease, lymph node, mesentery, small bowel  

Is Immediate Radical Cystectomy Necessary for All Patients with Non-Muscle-Invasive Micropapillary Bladder Cancer?

2015 ◽  
Vol 96 (1) ◽  
pp. 32-38 ◽  
Author(s):  
Benjamin L. Jackson ◽  
Aza Mohammed ◽  
Nick Mayer ◽  
John Dormer ◽  
T.R. Leyshon Griffiths
Keyword(s):  
Urothelial Carcinoma ◽  
Prognostic Indicator ◽  
Lymph Node Involvement ◽  
Morphological Marker ◽  
Free Survival ◽  
Non Invasive ◽  
Node Involvement ◽  
Resection Specimen ◽  
Muscle Invasive

Introduction: We aim to review the outcomes of micropapillary urothelial carcinoma (MPUC) of the bladder from a single institution. The hypothesis is that non-muscle-invasive (NMI) MPUC may have a heterogeneous prognosis, and detailed pathological analysis may identify patients that could be managed without immediate cystectomy. Patients and Methods: This is a retrospective analysis of patients presenting with MPUC in a primary transurethral resection specimen (n = 40). The pattern of micropapillary (MP) differentiation [surface/non-invasive (sMP) or invasive (iMP)], extent of MP differentiation and lymphovascular invasion (LVI) were correlated with overall survival (OS), recurrence-free survival and upstaging at re-resection. Results: Sixteen of 40 patients died after a median follow-up of 37 months. Tumour stage was strongly predictive of OS (p < 0.0001). LVI was associated with increased mortality (hazard ratio 12.4, 95% CI: 3.5-44.5, p = 0.0001), higher pathological stage (p = 0.001), lymph node involvement (p = 0.001) and iMP differentiation (p = 0.006). In NMI patients not undergoing cystectomy (n = 17), NMI-sMP compared with NMI-iMP differentiation was associated with an improved OS when compared with iMP (63 vs. 47 months, p = 0.05). Conclusions: MPUC is an aggressive variant of urothelial carcinoma (UC). Similar to conventional UC, LVI associated with MPUC is an adverse prognostic indicator. iMP is a morphological marker for LVI. Histopathological reports should distinguish between sMP and iMP differentiation.

scholarly journals Copy number gains at chr3p25 and chr11p11 are associated with lymph node involvement and survival in muscle-invasive bladder tumors

PLoS ONE ◽  
2017 ◽  
Vol 12 (11) ◽  
pp. e0187975
Author(s):  
Karla J. Lindquist ◽  
Thomas Sanford ◽  
Terence W. Friedlander ◽  
Pamela L. Paris ◽  
Sima P. Porten
Keyword(s):  
Lymph Node ◽  
Copy Number ◽  
Lymph Node Involvement ◽  
Bladder Tumors ◽  
Node Involvement ◽  
Muscle Invasive

scholarly journals Impact of 18F-FDG PET/CT on the staging of patients with non-small cell lung cancer

2020 ◽  
Vol 8 (6) ◽  
pp. 2023
Author(s):  
Ngo Minh Xuan ◽  
Huynh Quang Huy
Keyword(s):  
Lymph Node ◽  
Tumor Size ◽  
Distant Metastases ◽  
Large Cell ◽  
Lymph Node Involvement ◽  
Emission Tomography ◽  
Small Cell Lung ◽  
Positron Emission ◽  
Node Involvement ◽  
Group 3

Background: Non-small cell lung cancer (NSCLC) accounts for approximately 80% of new diagnoses of pulmonary carcinoma. This study investigated the correlation between 18 F-fluorodeoxyglucose uptake in computerized tomography integrated positron emission tomography and tumor size, lymph node metastasis, and distant metastasis in patients with NSCLC.Methods: The records of 318 NSCLC patients (220 male, 98 females; mean age 60.94 years) were evaluated retrospectively.Results: 278 cases were adenocarcinomas; 28 squamous cell carcinomas; and 12 large cell carcinoma. When the cases were categorized according to tumor size (group 1, ≤3 cm; group 2, >3 and ≤5 cm; group 3, >5 cm), the maximum standardized uptake value (SUVmax) was significantly lower in groups 1 and 2 compared with group 3 (p<0,001 for each). Considering all cases, tumor SUVmax was not correlated with age, gender or histopathological type. Lymph node metastases were seen in 250 cases: 80.2% of these were adenocarcinomas, 71.4% squamous cell carcinomas, and 58.3% large cell carcinomas. Neither lymph node involvement nor distant metastases were correlated with tumor SUVmax, although lymph node size was positively correlated with lymph node SUVmax (r=0.758; p<0.001).Conclusions: SUVmax was significantly associated with tumor size, but not with distant metastases or lymph node involvement. Therefore, SUVmax on positron emission tomography is not predictive of the presence of metastases. 

scholarly journals Extranodal Extension Predicts Poor Survival Outcomes among Patients with Bladder Cancer

Cancers ◽  
2021 ◽  
Vol 13 (16) ◽  
pp. 4108
Author(s):  
Yi-An Liao ◽  
Chun-Ju Chiang ◽  
Wen-Chung Lee ◽  
Bo-Zhi Zhuang ◽  
Chung-Hsin Chen ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Lymph Node ◽  
Adjuvant Chemotherapy ◽  
Cancer Patients ◽  
Radical Cystectomy ◽  
Lymph Node Involvement ◽  
Survival Outcomes ◽  
Nodal Disease ◽  
Extranodal Extension ◽  
Node Involvement

Background: Several lymph node-related prognosticators were reported in bladder cancer patients with lymph node involvement and receiving radical cystectomy. However, extranodal extension (ENE) remained a debate to predict outcomes. Methods: A retrospective analysis of 1303 bladder cancer patients receiving radical cystectomy and bilateral pelvic lymph node dissection were identified in the National Taiwan Cancer Registry database from 2011 to 2017. Based on the 304 patients with lymph node involvement, the presence of ENE and major clinical information were recorded and calculated. The overall survival (OS) and cancer-specific survival (CSS) were estimated with Kaplan–Meier analysis and compared using the log-rank test. Hazard ratios (HR) and the associated 95% confidence intervals were calculated in the univariate and stepwise multivariable models. Results: In the multivariable analysis, ENE significantly reduced OS (HR = 1.74, 95% CI 1.09–2.78) and CSS (HR = 1.69, 95% CI 1.01–2.83) more than non-ENE. In contrast, adjuvant chemotherapy was significantly associated with better OS and CSS upon the identification of pathological nodal disease. Conclusions: Reduced OS and CSS outcomes were observed in the pathological nodal bladder cancer patients with ENE compared with those without ENE. After the identification of pathological nodal disease, adjuvant chemotherapy was associated with better survival outcomes.

Sign in / Sign up

Export Citation Format

Share Document